iShares Trust. Holdings as of Jun 30, 2026, from Form N-PORT.
Share of net assets at the report date, for the whole fund across all share classes.
| Holding | Weight | Value | Shares or units |
|---|---|---|---|
| ELI LILLY AND COMPANYLLY | 10.93% | $420.26M | 350,380 |
| JOHNSON & JOHNSONJNJ | 7.04% | $270.79M | 1,066,210 |
| ABBVIE INC.ABBV | 5.12% | $196.92M | 782,552 |
| ASTRAZENECA PLC | 3.76% | $191.71M | 774,124 |
| Roche Holding AG | 3.75% | $178.40M | 350,659 |
| Novartis AG | 3.71% | $176.75M | 913,752 |
| UNITEDHEALTH GROUP INCORPORATEDUNH | 4.40% | $169.00M | 406,604 |
| MERCK & CO., INC.MRK | 4.12% | $158.40M | 1,232,696 |
| AMGEN INC.AMGN | 2.54% | $97.55M | 269,382 |
| THERMO FISHER SCIENTIFIC INCORPORATEDTMO | 2.42% | $92.98M | 185,465 |
| ABBOTT LABORATORIESABT | 2.05% | $78.89M | 869,383 |
| GILEAD SCIENCES, INC.GILD | 2.04% | $78.29M | 619,698 |
| GSK PLC | 1.38% | $70.47M | 2,023,757 |
| INTUITIVE SURGICAL, INC.ISRG | 1.83% | $70.30M | 176,770 |
| PFIZER INC.PFE | 1.78% | $68.50M | 2,844,791 |
| CVS HEALTH CORPORATIONCVS | 1.71% | $65.88M | 636,864 |
| VERTEX PHARMACEUTICALS INCORPORATEDVRTX | 1.64% | $62.93M | 126,687 |
| DANAHER CORPORATIONDHR | 1.56% | $59.89M | 314,415 |
| BRISTOL-MYERS SQUIBB COMPANYBMY | 1.53% | $58.73M | 1,019,269 |
| STRYKER CORPORATIONSYK | 1.41% | $54.22M | 172,214 |
| SANOFI SA | 1.18% | $52.01M | 532,395 |
| MEDTRONIC PUBLIC LIMITED COMPANYMDT | 1.30% | $50.13M | 640,826 |
| MCKESSON CORPORATIONMCK | 1.18% | $45.32M | 59,976 |
| ELEVANCE HEALTH, INC.ELV | 1.09% | $41.91M | 108,365 |
| BlackRock Funds III: BlackRock Cash Funds: Institutional; SL Agency SharesCash or money market | 1.06% | $40.61M | 40,597,301 |
| THE CIGNA GROUPCI | 0.95% | $36.40M | 132,026 |
| argenx SE | 0.74% | $32.70M | 30,878 |
| BOSTON SCIENTIFIC CORPORATIONBSX | 0.82% | $31.66M | 741,880 |
| ESSILORLUXOTTICA SA | 0.71% | $31.25M | 145,677 |
| REGENERON PHARMACEUTICALS, INC.REGN | 0.81% | $31.09M | 49,855 |
| Bayer Aktiengesellschaft | 0.71% | $30.99M | 490,353 |
| HCA HEALTHCARE, INC.HCA | 0.79% | $30.22M | 77,505 |
| Lonza Group AG | 0.61% | $29.25M | 35,038 |
| CARDINAL HEALTH, INC.CAH | 0.72% | $27.77M | 116,886 |
| CENCORA, INC.COR | 0.71% | $27.48M | 97,108 |
| HALEON PLC | 0.53% | $27.05M | 4,426,055 |
| EDWARDS LIFESCIENCES CORPORATIONEW | 0.68% | $26.00M | 287,370 |
| Galderma Group AG | 0.54% | $25.73M | 91,412 |
| Sandoz Group AG | 0.52% | $24.56M | 219,596 |
| HUMANA INC.HUM | 0.62% | $23.80M | 59,913 |
| Alcon AG | 0.44% | $20.81M | 249,391 |
| IDEXX LABORATORIES, INC.IDXX | 0.54% | $20.72M | 39,363 |
| BECTON, DICKINSON AND COMPANYBDX | 0.54% | $20.71M | 136,853 |
| UCB SA | 0.47% | $20.58M | 60,174 |
| AGILENT TECHNOLOGIES, INC.A | 0.49% | $18.74M | 141,050 |
| WATERS CORPORATIONWAT | 0.48% | $18.38M | 48,997 |
| IQVIA HOLDINGS INCIQV | 0.42% | $16.09M | 83,286 |
| BIOGEN INC.BIIB | 0.41% | $15.92M | 73,693 |
| ZOETIS INC.ZTS | 0.39% | $15.04M | 209,235 |
| CENTENE CORPORATIONCNC | 0.39% | $15.03M | 234,154 |
Holdings from the fund's latest Form N-PORT; expense ratio (net of fee waivers) from the risk/return summary of its prospectus; fund type from Form N-CEN. Prices are end-of-day closes adjusted for splits; total return also reinvests distributions.